Prostatype® – a new gene test for prostate cancer patients
Based on genetic profile and clinical data of the tested patient, the P-score is estimated. The P-score indicates the aggressiveness of the tumor. The prostate cancer-specific mortality risk at 10 years for a patient with a low P-score (green) is below 3.4%, for an intermediate P-score (yellow) it is below 10.8%. In addition, the software identifies the three most similar reference patients from an authentic historic database. The treatment, survival time and cause of death of the reference patients is displayed and serve as a decision support when choosing the optimal treatment for the patient.